Limited Neutralization of Authentic Severe Acute Respiratory Syndrome Coronavirus 2 Variants Carrying E484K In Vitro

作者：Marek Widera, Alexander Wilhelm, Sebastian Hoehl, Christiane Pallas, Niko Kohmer, Timo Wolf, Holger Felix Rabenau, Victor M. Corman, Christian Drosten, Maria J. G. T. Vehreschild, Udo Goetsch, René Gottschalk, Sandra Ciesek · 发表于：The Journal of Infectious Diseases · 年份：2021 · DOI：10.1093/infdis/jiab355 · 被引用次数：69 · 研究领域：SARS-CoV-2 and COVID-19 Research、Animal Virus Infections Studies、COVID-19 Clinical Research Studies

Whether monoclonal antibodies are able to neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern has been investigated using pseudoviruses. In this study we show that bamlanivimab, casirivimab, and imdevimab efficiently neutralize authentic SARS-CoV-2, including variant B.1.1.7 (alpha), but variants B.1.351 (beta) and P.2 (zeta) were resistant against bamlanivimab and partially resistant to casirivimab. Whether antibodies are able to neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variantshas been investigated using pseudoviruses. We show that authentic SARS-CoV-2 carrying E484K were resistant against bamlanivimab and less susceptible to casirivimab, convalescent and vaccine-elicited sera.